AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Choroideremia (CHM) is an X- linked retinal degeneration that is symptomatic in the 1(st) or 2(nd) decade of life causing nyctalopia and loss of peripheral vision. The disease progresses through mid-life, when most patients become blind. CHM is a favorable target for gene augmentation therapy, as the disease is due to loss of function of a protein necessary for retinal cell health, Rab Escort Protein 1 (REP1).The CHM cDNA can be packaged in recombinant adeno-associated virus (rAAV), which has an established track record in human gene therapy studies, and, in addition, there are sensitive and quantitative assays to document REP1 activity. An animal model that accurately reflects the human condition is not available. In this study, we tested the ability to restore REP1 function in personalized in vitro models of CHM: lymphoblasts and induced pluripotent stems cells (iPSCs) from human patients. The initial step of evaluating safety of the treatment was carried out by evaluating for acute retinal histopathologic effects in normal-sighted mice and no obvious toxicity was identified. Delivery of the CHM cDNA to affected cells restores REP1 enzymatic activity and also restores proper protein trafficking. The gene transfer is efficient and the preliminary safety data are encouraging. These studies pave the way for a human clinical trial of gene therapy for CHM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rab proteins as membrane organizers
Zerial, M., & McBride, H. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052055 · Cited by 3,381
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In the present study, we generated a vector using components very similar to those of the vector that we used successfully in Phase I/II studies in a clinical trial for Leber Congenital Amaurosis due to RPE65 mutations (LCA-RPE65), an AAV vector with serotype 2 capsid [25,50,51,52].”
MethodSelf-citationMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citationSomers, A., Jean, J.-C., Sommer, C. A., Omari, A., Ford, C. C., Mills, J. A., Ying, L., Sommer, A. G., Jean, J. M., Smith, B. W., et al. (2010) · Stem Cells · doi:10.1002/stem.495 · Cited by 423
Self-citationRetinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase
Seabra, M. C., Brown, M. S., & Goldstein, J. L. (1993) · Science · doi:10.1126/science.8380507 · Cited by 337 · cited 1×
“were isolated and used to perform in vitro prenylation assays in which the cytosolic cellular fraction served as the REP-1 protein source, RabGGTase, [(3)H]-GGPP as the prenyl group donor, and recombinant RAB27 as the substrate, as described previously [30,38,39].”
MethodAmado, D., Mingozzi, F., Hui, D., Bennicelli, J. L., Wei, Z., Chen, Y., Bote, E., Grant, R. L., Golden, J. A., Narfstrom, K., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000659 · Cited by 140
Self-citation
Research works printed but not linked: 44
- IM MacDonald, 2009, Choroideremia: new findings from ocular pathology and review of recent literature, Surv Ophthalmol, 54, 401, 10.1016/j.survophthal.2009.02.008 · DOI
- EV Rafuse, 1968, Choroideremia. A pathological report, Can J Ophthalmol, 3, 347
- RG Coussa, 2012, Choroideremia: effect of age on visual acuity in patients and female carriers, Ophthalmic Genet, 33, 66, 10.3109/13816810.2011.623261 · DOI
- RG Coussa, 2012, Choroideremia: a review of general findings and pathogenesis, Ophthalmic Genet, 33, 57, 10.3109/13816810.2011.620056 · DOI · Paper page
- MC Seabra, 1996, New insights into the pathogenesis of choroideremia: a tale of two REPs, Ophthalmic Genet, 17, 43, 10.3109/13816819609057869 · DOI
- JA van den Hurk, 1997, Molecular basis of choroideremia (CHM): mutations involving the Rab escort protein-1 (REP-1) gene, Hum Mutat, 9, 110, 10.1002/(SICI)1098-1004(1997)9:2<110::AID-HUMU2>3.0.CO;2-D · DOI · Paper page
- JG Flannery, 1990, A histopathologic study of a choroideremia carrier, Invest Ophthalmol Vis Sci, 31, 229
- HJ Perez-Cano, 2009, CHM gene molecular analysis and X-chromosome inactivation pattern determination in two families with choroideremia, Am J Med Genet A, 149A, 2134, 10.1002/ajmg.a.32727 · DOI
- S Pfeffer, 2004, Targeting Rab GTPases to distinct membrane compartments, Nat Rev Mol Cell Biol, 5, 886, 10.1038/nrm1500 · DOI · Paper page
- FL Zhang, 1996, Protein prenylation: molecular mechanisms and functional consequences, Annu Rev Biochem, 65, 241, 10.1146/annurev.bi.65.070196.001325 · DOI · Paper page
- K Alexandrov, 1994, Rab escort protein-1 is a multifunctional protein that accompanies newly prenylated rab proteins to their target membranes, EMBO Journal, 13, 5262, 10.1002/j.1460-2075.1994.tb06860.x · DOI · Paper page
- A Rak, 2004, Structure of the Rab7:REP-1 complex: insights into the mechanism of Rab prenylation and choroideremia disease, Cell, 117, 749, 10.1016/j.cell.2004.05.017 · DOI · Paper page
- YV Sergeev, 2009, The functional effect of pathogenic mutations in Rab escort protein 1, Mutat Res, 665, 44, 10.1016/j.mrfmmm.2009.02.015 · DOI · Paper page
- NV Strunnikova, 2009, Loss-of-function mutations in Rab escort protein 1 (REP-1) affect intracellular transport in fibroblasts and monocytes of choroideremia patients, PLoS One, 4, e8402, 10.1371/journal.pone.0008402 · DOI · Paper page
- MC Seabra, 1995, Deficient geranylgeranylation of Ram/Rab27 in choroideremia, J Biol Chem, 270, 24420, 10.1074/jbc.270.41.24420 · DOI · Paper page
- FP Cremers, 1994, REP-2, a Rab escort protein encoded by the choroideremia-like gene, J Biol Chem, 269, 2111, 10.1016/S0021-9258(17)42142-9 · DOI · Paper page
- FPM Cremers, 1992, An autosomal homologue of the choroideremia gene colocalizes with the Usher syndrome type II locus on the distal part of chromosome 1q, Hum Mol Genet, 1, 71, 10.1093/hmg/1.2.71 · DOI · Paper page
- H van Bokhoven, 1994, Mutation spectrum in the CHM gene of Danish and Swedish choroideremia patients, Hum Mol Genet, 3, 1047, 10.1093/hmg/3.7.1047 · doi:10.1093/hmg/3.7.1047
- E-M Sankila, 1992, Aberrant splicing of the CHM gene is a significant cause of choroideremia, Nature Genetics, 1, 109, 10.1038/ng0592-109 · DOI
- FRM Cremers, 1990, Deletions in patients with classical choroideremia vary in size from 45 kb to several megabases, American Journal of Human Genetics, 47, 622
- N Keiser, 2005, Spatial and temporal expression patterns of the choroideremia gene in the mouse retina, Mol Vis, 11, 1052
- Lipinski DM, Thake M, Maclaren RE (2012) Clinical applications of retinal gene therapy. Prog Retin Eye Res. · DOI
- J Bennett, 2012, AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness, Sci Transl Med, 4, 120ra115, 10.1126/scitranslmed.3002865 · DOI · Paper page
- RW Herzog, 1999, Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy, Thromb Haemost, 82, 540, 10.1055/s-0037-1615877 · DOI
- D Grimm, 2003, Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy, Blood, 102, 2412, 10.1182/blood-2003-02-0495 · DOI · Paper page
- P Forsythe, 1997, A carboxy-terminal truncation of 99 amino acids resulting from a novel mutation (Arg555-> stop) in the CHM gene leads to Choroideremia, Experimental Eye Research, 64, 487, 10.1006/exer.1996.0200 · doi:10.1006/exer.1996.0200
- V Vasireddy, 2011, Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation, PLoS One, 6, e21193, 10.1371/journal.pone.0021193 · DOI
- V Anand, 2003, Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus, Vision Res, 43, 919, 10.1016/S0042-6989(02)00389-9 · DOI
- JM Polo, 2010, When fibroblasts MET iPSCs, Cell Stem Cell, 7, 5, 10.1016/j.stem.2010.05.018 · DOI
- JM Polo, 2010, Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells, Nat Biotechnol, 28, 848, 10.1038/nbt.1667 · DOI · Paper page
- PH Lerou, 2008, Derivation and maintenance of human embryonic stem cells from poor-quality in vitro fertilization embryos, Nat Protoc, 3, 923, 10.1038/nprot.2008.60 · DOI
- PH Lerou, 2008, Human embryonic stem cell derivation from poor-quality embryos, Nat Biotechnol, 26, 212, 10.1038/nbt1378 · DOI
- K Kim, 2010, Epigenetic memory in induced pluripotent stem cells, Nature, 467, 285, 10.1038/nature09342 · DOI · Paper page
- MC Seabra, 1992, Purification of component A of Rab geranylgeranyl transferase: Possible identity with the choroideremia gene product, Cell, 70, 1049, 10.1016/0092-8674(92)90253-9 · DOI · Paper page
- Basiji DA, Ortyn WE, Liang L, Venkatachalam V, Morrissey P (2007) Cellular image analysis and imaging by flow cytometry. Clin Lab Med 27: 653–670, viii. · DOI · Paper page
- KE McGrath, 2008, Multispectral imaging of hematopoietic cells: where flow meets morphology, J Immunol Methods, 336, 91, 10.1016/j.jim.2008.04.012 · DOI
- T Tolmachova, 2006, Independent degeneration of photoreceptors and retinal pigment epithelium in conditional knockout mouse models of choroideremia, J Clin Invest, 116, 386, 10.1172/JCI26617 · DOI · Paper page
- T Tolmachova, 2012, CHM/REP1 cDNA delivery by lentiviral vectors provides functional expression of the transgene in the retinal pigment epithelium of choroideremia mice, J Gene Med, 14, 158, 10.1002/jgm.1652 · DOI · Paper page
- JS Meyer, 2009, Modeling early retinal development with human embryonic and induced pluripotent stem cells, Proc Natl Acad Sci U S A, 106, 16698, 10.1073/pnas.0905245106 · DOI · Paper page
- MJ Phillips, 2012, Blood-derived human iPS cells generate optic vesicle-like structures with the capacity to form retinal laminae and develop synapses, Invest Ophthalmol Vis Sci, 53, 2007, 10.1167/iovs.11-9313 · DOI · Paper page
- O Pylypenko, 2003, Structure of Rab escort protein-1 in complex with Rab geranylgeranyltransferase, Mol Cell, 11, 483, 10.1016/S1097-2765(03)00044-3 · DOI
- LM Hoffman, 1997, Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery, Invest Ophthalmol Vis Sci, 38, 2224
- SE Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol Genet Metab, 80, 148, 10.1016/j.ymgme.2003.08.016 · DOI · Paper page
- F Simonelli, 2010, Gene Therapy for Leber’s Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration, Mol Ther, 18, 643, 10.1038/mt.2009.277 · DOI · Paper page
Cited by
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
Choroideremia gene therapy phase 2 clinical trial: 24-month results
Lam, B. L., Davis, J. L., Gregori, N. Z., MacLaren, R. E., Girach, A., Verriotto, J. D., Rodriguez, B., Rosa, P. R., Zhang, X., & Feuer, W. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.09.012 · Cited by 161
Constable, I. J., Pierce, C. M., Lai, C.-M., Magno, A. L., Degli-Esposti, M. A., French, M. A., McAllister, I. L., Butler, S., Barone, S. B., Schwartz, S. D., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.016 · Cited by 152
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
“Classically, choroideremia is characterized by atrophy of the choroid, resulting in pallor in the outer retina with progressive vision loss and night blindness (78).”
BackgroundGene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
Metadata
- Authors
- Vasireddy, V., Mills, J. A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A. D., Alexandrov, K., Zhou, S., Maguire, A. M., Chung, D. C., Mac, H., Sullivan, L., Gadue, P., Bennicelli, J. L., French, D. L., & Bennett, J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-07
- Volume
- 8
- Issue
- 5
- Pages
- e61396
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2117381269
- Cited by
- 79
- References
- 7
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-06-19)
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models. https://app.cochat.ai/papers/10.1371/journal.pone.0061396
- The paper
- Vasireddy, V., Mills, J. A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A. D., Alexandrov, K., Zhou, S., Maguire, A. M., Chung, D. C., Mac, H., Sullivan, L., Gadue, P., Bennicelli, J. L., French, D. L., & Bennett, J. (2013). AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models. PLoS ONE. https://doi.org/10.1371/journal.pone.0061396
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.